MD3222G2 - Метод диагностики рака эндометрия - Google Patents

Метод диагностики рака эндометрия Download PDF

Info

Publication number
MD3222G2
MD3222G2 MDA20060093A MD20060093A MD3222G2 MD 3222 G2 MD3222 G2 MD 3222G2 MD A20060093 A MDA20060093 A MD A20060093A MD 20060093 A MD20060093 A MD 20060093A MD 3222 G2 MD3222 G2 MD 3222G2
Authority
MD
Moldova
Prior art keywords
endometrial cancer
endometrial
diagnosis
cancer diagnosis
determining
Prior art date
Application number
MDA20060093A
Other languages
English (en)
Romanian (ro)
Other versions
MD3222F1 (en
Inventor
Думитру СОФРОНИ
Лилиан ГУЦУ
Катйа ТЕННЕР
Анатол ЧЕРНЫЙ
Михаил ТОДИРАШ
Майкл БАДЕР
Original Assignee
Общественное Медико-Санитарное Учреждение Онкологический Институт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общественное Медико-Санитарное Учреждение Онкологический Институт filed Critical Общественное Медико-Санитарное Учреждение Онкологический Институт
Priority to MDA20060093A priority Critical patent/MD3222G2/ru
Publication of MD3222F1 publication Critical patent/MD3222F1/xx
Publication of MD3222G2 publication Critical patent/MD3222G2/ru

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к медицине, в частности к онкологии и может быть использовано для ранней неинвазивной диагностики и для подтверждения диагноза рака эндометрия.Сущность изобретения состоит в определении концентрации информационной РНК триптофангидроксилазы -1 в тканях эндометрия и миометрия, и в случае, когда в ткани эндометрия концентрация в 2…100 раз больше, устанавливают диагноз рака эндометрия.Результат изобретения состоит в возможности ранней дифференциальной диагностики рака эндометрия для определения до- и постоперационного эффективного метода лечения.
MDA20060093A 2006-03-22 2006-03-22 Метод диагностики рака эндометрия MD3222G2 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (ru) 2006-03-22 2006-03-22 Метод диагностики рака эндометрия

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060093A MD3222G2 (ru) 2006-03-22 2006-03-22 Метод диагностики рака эндометрия

Publications (2)

Publication Number Publication Date
MD3222F1 MD3222F1 (en) 2007-01-31
MD3222G2 true MD3222G2 (ru) 2007-08-31

Family

ID=37776647

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060093A MD3222G2 (ru) 2006-03-22 2006-03-22 Метод диагностики рака эндометрия

Country Status (1)

Country Link
MD (1) MD3222G2 (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3499G2 (ru) * 2007-10-12 2008-09-30 Общественное Медико-Санитарное Учреждение Онкологический Институт Метод дифференцированного лечения рака эндометрия
MD492Z (ru) * 2011-08-17 2012-10-31 Лорена МЕДНИКОВ Метод определения распространения кишечного типа рака желудка

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
H, Chen G, Zhang B. Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma Zhonghua Bing Li Xue *
Iwanari O, Miyako J, Date Y, Nakayama S, Kijima S, Moriyama M, Karino K, Endoh J, Kitao M.Clinical evaluations of the tumor marker sialyl *
Iwanari O., Miyako J., Date Y., Nakayama S., Kijima S., Moriyama M., Karino K., Endoh J., Kitao M. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease. Gynecol Obstet Invest. 1990, № 29, p. 214-218 *
Jacobs I, Bast RC: The CA125 tumour-associated antigen: a review of the literature. *
Jacobs I., Bast R. The CA125 tumour-associated antigen: a review of the literature. *
SSEA-1 antigen for clinical gynecological disease. Gynecol Obstet Invest. 1990, № 29, p. 214-218 *
Sung C., Zheng Y., Quddus M., Kang X., Zhang Z., Lauchlan S., Zheng W. P53 as a significant prognostic marker in endometrial carcinoma. Int J Gynecol Cancer. 2000 Mar, № 10(2), p. 119-127 *
Sung CJ, Zheng Y, Quddus MR, Kang X, Zhang ZF, Lauchlan SC, Zheng W.p53 as a significant prognostic marker in endometrial carcinoma. Int *
Wang H., Chen G., Zhang B. Expression of vascular endothelial growth factor and its receptors in endometrial carcinoma. Zhonghua Bing Li Xue Za Zhi. 2002, № 31(5), p. 391-395 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3499G2 (ru) * 2007-10-12 2008-09-30 Общественное Медико-Санитарное Учреждение Онкологический Институт Метод дифференцированного лечения рака эндометрия
MD492Z (ru) * 2011-08-17 2012-10-31 Лорена МЕДНИКОВ Метод определения распространения кишечного типа рака желудка

Also Published As

Publication number Publication date
MD3222F1 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
LUC00011I2 (ru)
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
EP1844077A4 (en) DR5 ANTIBODIES AND THEIR USE
EP2985281A3 (en) Isoindoline compounds for use in the treatment of cancer
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
TW200606162A (en) Pyrazolopyridine derivatives
MXPA05008478A (es) Heterociclos sustituidos.
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
TW200806293A (en) Methods of treatment with CETP inhibitors
WO2007120720A3 (en) Uses and compositions for treatment of crohn's disease
MD3222G2 (ru) Метод диагностики рака эндометрия
AU2006332806A8 (en) Na+, K+-ATPase expression in cervical dysplasia and cancer
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
WO2007118077A3 (en) Mycobacterial catalase-peroxidase in the diagnosis and treatment of sarcoidosis
WO2007146375A3 (en) Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
WO2007110704A3 (en) Macrolide compositions as therapeutic agent
WO2007110705A3 (en) Macrolide as inhibitors of mhc class ii
MD3244G2 (ru) Метод определения агрессивности рака эндометрия
WO2007033096A3 (en) Methods and compositions for diagnosis and treatment of disorders involving macrophages
WO2005027851A3 (en) Treatment of severe distal colitis

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees